文献速递眼底病与葡萄膜炎

黄斑快速变薄是羟氯喹视网膜毒性的早期指标

Rapid Macular Thinning Is an Early Indicator of Hydroxychloroquine Retinal Toxicity.
PubMed 文献 · Ophthalmology · 2022-05-11

该回顾性病例队列研究纳入301例长期接受羟氯喹治疗且至少有4次OCT检查(含ETDRS视网膜厚度值)并随访至少4年的患者,通过系列视网膜厚度图识别快速黄斑变薄。219例稳定患者视网膜变薄平均0.62±0.45微米/年,82例快速变薄患者为3.75±1.34微米/年;其中38例最终出现常规OCT或10-2视野的羟氯喹视网膜毒性体征,其累积视网膜变薄25.1±6.2微米,而无常规毒性体征者为15.7±4.0微米(P<0.01)。结论认为连续ETDRS环黄斑厚度图可在常规体征出现前数年提供早期结构改变的客观证据。

要点

  • 长期羟氯喹治疗患者中,视网膜厚度多年保持稳定,但部分患者可出现快速变薄。
  • 快速变薄患者累积视网膜变薄25.1±6.2微米,高于无常规毒性体征者的15.7±4.0微米(P<0.01)。
  • 连续ETDRS环黄斑厚度图可在常规OCT或10-2视野体征出现前数年提示早期结构改变。

核心结论

  • 大多数长期接受羟氯喹治疗的患者视网膜厚度多年保持稳定,但经过某一临界点后视网膜可能开始快速变薄。
  • 连续绘制内环和外环ETDRS黄斑厚度图可在常规体征出现前数年提供这种早期结构改变的客观证据。
  • 该方法可提醒患者和处方医生注意潜在视网膜损害,且使用现有OCT测量值,制造商可将其自动化以用于综合眼科诊疗环境。

研究设计与样本

  • 回顾性病例队列研究,纳入301例在Kaiser Permanente北加州接受长期羟氯喹治疗的患者。
  • 患者至少完成4次OCT检查,包含ETDRS视网膜厚度值,随访至少4年。
  • 通过创建系列视网膜厚度图来显示ETDRS区域内黄斑厚度的变化速率。

主要发现

  • 219例稳定患者视网膜变薄平均为0.62±0.45微米/年。
  • 82例患者出现相对线性的快速变薄期,年丢失量为3.75±1.34微米/年。
  • 快速变薄患者中38例最终出现常规OCT或10-2视野的羟氯喹视网膜毒性体征。
  • 出现常规毒性体征者累积视网膜变薄25.1±6.2微米,未出现者为15.7±4.0微米(P<0.01)。

临床怎么用

  • 连续绘制内环和外环ETDRS黄斑厚度图可提供早期结构改变的客观证据,该方法可提醒患者和处方医生注意潜在视网膜损害。
  • 该方法使用现有OCT测量值,制造商可将其自动化以用于综合眼科诊疗环境。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To demonstrate rapid macular thinning as an early and objective sign of hydroxychloroquine retinopathy. DESIGN: Retrospective case cohort. PARTICIPANTS: Cohort of 301 patients receiving long-term hydroxychloroquine therapy at Kaiser Permanente Northern California who underwent a minimum of 4 OCT studies that included Early Treatment Diabetic Retinopathy Study (ETDRS) retinal thickness values over a minimum of 4 years. METHODS: Creation of sequential retinal thickness plots to show the rate of change in macular thickness within ETDRS regions. MAIN OUTCOME MEASURES: Identification of rapid macular thinning, comparison of patients with rapid thinning to those with stable macular thickness, and comparison of rapid thinning patients with and without conventional OCT or 10-2 visual field signs of hydroxychloroquine toxicity. RESULTS: Retina thinning in 219 stable patients receiving long-term hydroxychloroquine therapy averaged (mean ± standard deviation) 0.62 ± 0.45 μm/year, whereas 82 patients showed a period of relatively linear rapid thinning with a loss of 3.75 ± 1.34 μm/year. Of the patients with rapid thinning, 38 eventually demonstrated conventional OCT or 10-2 visual field signs of hydroxychloroquine retinal toxicity. The cumulative retinal thinning in these patients was 25.1 ± 6.2 μm compared with 15.7 ± 4.0 μm in those without conventional toxicity (P < 0.01). CONCLUSIONS: Retinal thickness remains stable for many years in most patients receiving long-term hydroxychloroquine therapy, but after a critical point, the retina may begin to thin rapidly. Sequential plots of inner and outer ETDRS ring macular thickness provide objective evidence of this early structural change several years before conventional signs appear. This approach can alert patients and prescribing physicians to potential retinal damage and uses readily available OCT measurements that could be automated by manufacturers for use in comprehensive eye care settings.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Melles RB, Marmor MF. Rapid Macular Thinning Is an Early Indicator of Hydroxychloroquine Retinal Toxicity. Ophthalmology. 2022. PMID: 35568277. doi:10.1016/j.ophtha.2022.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。